Fig. 1From: Janus kinase inhibitors vs. abatacept about safety and efficacy for patients with rheumatoid arthritis-associated interstitial lung disease: a retrospective nested case-control studyFlow diagram of the studySixty-one patients (JAKi: 26 patients, ABT: 45 patients) were recruited. After a propensity score matching analysis, 21 patients were assigned to each groupJAKi: Janus Kinase inhibitor; ABT: abataceptBack to article page